Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Neurodegenerative Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533877

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533877

Multiple Sclerosis Drugs

PUBLISHED:
PAGES: 235 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Multiple Sclerosis Drugs Market to Reach US$33.8 Billion by 2030

The global market for Multiple Sclerosis Drugs estimated at US$21.3 Billion in the year 2023, is expected to reach US$33.8 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2023-2030. Immmunomoderator Drugs, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$13.2 Billion by the end of the analysis period. Growth in the Immunosuppresant Drugs segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.6 Billion While China is Forecast to Grow at 6.6% CAGR

The Multiple Sclerosis Drugs market in the U.S. is estimated at US$5.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$5.4 Billion by the year 2030 trailing a CAGR of 6.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.4% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Key Trends and Drivers

Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder characterized by the immune system attacking the myelin sheath that covers nerve fibers, leading to disrupted communication between the brain and the body. The treatment of MS has improved dramatically with the introduction of disease-modifying therapies (DMTs) that help reduce the frequency and severity of attacks, slow disease progression, and manage symptoms. These therapies include injectable medications, such as interferons and glatiramer acetate, oral drugs like fingolimod and dimethyl fumarate, and infusion treatments such as natalizumab and ocrelizumab. The diversity of available treatments allows personalized care plans that are tailored to the severity of the disease, the specific symptoms experienced by the patient, and their lifestyle preferences.

In recent years, the focus of MS treatment has shifted towards earlier intervention and more aggressive treatment strategies to prevent irreversible neurological damage. Newer therapies that target specific pathways involved in the MS disease process are in development, offering potential improvements in efficacy and safety compared to older therapies. Research is also exploring the role of lifestyle factors, rehabilitation, and symptom management therapies to improve the quality of life for MS patients. This holistic approach to MS care is increasingly recognized as essential for managing the disease effectively.

The growth in the multiple sclerosis drugs market is driven by several factors, including ongoing advancements in the understanding of MS pathology that lead to novel therapeutic targets and drug development. Increased prevalence of MS across the globe and the rising demand for more effective and safer treatments fuel the market's expansion. Furthermore, the approval of new and innovative drugs by regulatory bodies accelerates their adoption in clinical practice. The market is also supported by robust patient advocacy networks that promote awareness, education, and access to new treatments, ensuring that patients benefit from the latest advances in MS care. Additionally, improvements in diagnostic technologies aid in earlier detection and treatment initiation, which is critical for optimal management of the disease.

Select Competitors (Total 49 Featured) -

  • AB Science SA
  • Acorda Therapeutics, Inc.
  • Banner Life Sciences
  • Biogen, Inc.
  • Biohaven, Ltd.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Janssen Sciences Ireland UC
  • MediciNova, Inc.
  • Novartis International AG
  • Opexa Therapeutics, Inc.
  • Sandoz Group AG
  • Sanofi SA
  • Teva Pharmaceuticals USA, Inc.
  • TG Therapeutics, Inc.;
Show more
Product Code: MCP26831

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Multiple Sclerosis Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Innovations in Neuroprotective Treatment Approaches
    • Rising Prevalence of Multiple Sclerosis Worldwide
    • New Developments in Disease-Modifying Therapies (DMTs)
    • Clinical Trial Landscapes and Their Role in Therapy Advancements
    • Regulatory Incentives for Accelerated Drug Approval
    • Technological Advancements in Drug Administration
    • Increased Awareness and Diagnosis Rates Boosting Treatment Adoption
    • Global Expansion and Localization of Drug Production
    • Market Challenges Related to High Treatment Costs
    • Advocacy and Educational Efforts Improving Treatment Outcomes
    • The Future of Treatment: Potential for a Cure and Preventive Measures
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multiple Sclerosis Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Multiple Sclerosis Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Multiple Sclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Immmunomoderator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Immmunomoderator Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Immmunomoderator Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunosuppresant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunosuppresant Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunosuppresant Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Interferon Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Interferon Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Interferon Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • JAPAN
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • CHINA
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • EUROPE
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Multiple Sclerosis Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • FRANCE
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • GERMANY
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Europe 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Multiple Sclerosis Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Asia-Pacific 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Multiple Sclerosis Drugs by Drug Class - Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Multiple Sclerosis Drugs by Drug Class - Percentage Breakdown of Value Sales for Immmunomoderator Drugs, Immunosuppresant Drugs, Interferon Drugs and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Multiple Sclerosis Drugs by Distribuion Channel - Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Multiple Sclerosis Drugs by Distribuion Channel - Percentage Breakdown of Value Sales for Other Distribution Channels, Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Multiple Sclerosis Drugs by Route Of Administration - Oral Administration and Injectable Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of World 16-Year Perspective for Multiple Sclerosis Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral Administration and Injectable Administration for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!